Amneal’s second quarter results reflected a mixed performance, with revenue growth falling short of Wall Street expectations but profitability coming in notably ahead of analyst forecasts. Management highlighted strong execution within its specialty medicines segment, particularly the CREXONT launch for Parkinson’s disease and steady uptake across branded products. CFO Anastasios Konidaris pointed to "favorable product mix in each of the 3 segments and ongoing operating efficiencies" as key contributors to margin improvement, even as the company faced headwinds in its AvKARE distribution business.
Is now the time to buy AMRX? Find out in our full research report (it’s free).
Amneal (AMRX) Q2 CY2025 Highlights:
- Revenue: $724.5 million vs analyst estimates of $742.8 million (3.2% year-on-year growth, 2.5% miss)
- Adjusted EPS: $0.25 vs analyst estimates of $0.17 (42.9% beat)
- Adjusted EBITDA: $183.7 million vs analyst estimates of $175 million (25.3% margin, 5% beat)
- The company reconfirmed its revenue guidance for the full year of $3.05 billion at the midpoint
- Management raised its full-year Adjusted EPS guidance to $0.73 at the midpoint, a 7.4% increase
- EBITDA guidance for the full year is $675 million at the midpoint, in line with analyst expectations
- Operating Margin: 15.4%, up from 13.6% in the same quarter last year
- Market Capitalization: $2.83 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Amneal’s Q2 Earnings Call
- David Amsellem (Piper Sandler) asked about the timing and impact of RYTARY’s loss of exclusivity and the prospects for CREXONT to offset related headwinds. CFO Anastasios Konidaris explained the revenue trough is likely next year, with confidence that broader business growth will mitigate profitability impacts.
- David Amsellem (Piper Sandler) also inquired about the profitability of the Metsera collaboration. Co-CEO Chirag K. Patel said margins are expected to be higher than traditional generics due to upfront risk-taking, but specifics will become clearer as the business scales in 2026.
- Leszek Sulewski (Truist Securities) sought updates on RYTARY generics, CREXONT reimbursement, and international launches. Head of Specialty Commercial Joe Renda reported CREXONT coverage at over 60% of commercial payors, with continued progress toward broader access.
- Ekaterina V. Knyazkova (JPMorgan, for Chris Schott) questioned the drivers of second-half revenue acceleration and tariff risks. Management cited new product momentum, facility upgrades, and a strong government business pipeline, while noting limited exposure to international tariffs.
- Matthew Michael Dellatorre (Goldman Sachs) asked about AvKARE segment growth and vertical integration in biosimilars. Konidaris projected stronger AvKARE performance in the second half and emphasized disciplined capital allocation for biosimilar expansion, balancing growth with leverage targets.
Catalysts in Upcoming Quarters
In upcoming quarters, our team will watch (1) the pace and breadth of new specialty product launches—especially Brekiya and additional generics, (2) execution on biosimilar filings and advancement of the XOLAIR program, and (3) progress on the Metsera GLP-1 collaboration and manufacturing ramp. Progress on U.S. and international expansion, as well as tariff policy developments, will be additional factors influencing Amneal’s outlook.
Amneal currently trades at $9.03, up from $7.98 just before the earnings. Is the company at an inflection point that warrants a buy or sell? The answer lies in our full research report (it’s free).
The Best Stocks for High-Quality Investors
Trump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.
Take advantage of the rebound by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
